Author

Manon C.W. Spaander

Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021
Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2021

Manon C.W. Spaander

COLONOSCOPY QUALITY ASSURANCE IN AN ORGANIZED FIT-BASED COLORECTAL CANCER SCREENING PROGRAM
COLONOSCOPY QUALITY ASSURANCE IN AN ORGANIZED FIT-BASED COLORECTAL CANCER SCREENING PROGRAM

Manon C.W. Spaander  et al.

PPI, Aspirin and co: What is the evidence?
PPI, Aspirin and co: What is the evidence?

Manon C.W. Spaander

Cancer detection in the young adult: Screening, surveillance and stratification
Cancer detection in the young adult: Screening, surveillance and stratification

Manon C.W. Spaander

Benign oesophageal stricture
Benign oesophageal stricture

Manon C.W. Spaander

Caustic lesions in the oesophagus
Caustic lesions in the oesophagus

Manon C.W. Spaander

INCREASED RISK OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH SQUAMOUS DYSPLASIA: A NATIONWIDE COHORT STUDY IN THE NETHERLANDS
INCREASED RISK OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN PATIENTS WITH SQUAMOUS DYSPLASIA: A NATIONWIDE COHORT STUDY IN THE NETHERLANDS

Manon C.W. Spaander  et al.

ENDOSCOPIC REASSESSMENT OF CT2N0M0 ESOPHAGEAL ADENOCARCINOMA LEADS TO DOWNSTAGING TO T1 TUMORS AND PREVENTS UNNECESSARY ADJUVANT TREATMENT: A MULTICENTER PROSPECTIVE COHORT STUDY
ENDOSCOPIC REASSESSMENT OF CT2N0M0 ESOPHAGEAL ADENOCARCINOMA LEADS TO DOWNSTAGING TO T1 TUMORS AND PREVENTS UNNECESSARY ADJUVANT TREATMENT: A MULTICENTER PROSPECTIVE COHORT STUDY

Manon C.W. Spaander  et al.

LESS CRC RECURRENCE IN SCREEN-DETECTED COMPARED TO NON-SCREEN-DETECTED COLORECTAL CANCER PATIENTS
LESS CRC RECURRENCE IN SCREEN-DETECTED COMPARED TO NON-SCREEN-DETECTED COLORECTAL CANCER PATIENTS

Manon C.W. Spaander  et al.

IMPACT OF DELAYED SCREENING INVITATIONS DUE TO COVID-19 ON OUTCOMES OF THE DUTCH FIT-BASED COLORECTAL CANCER SCREENING PROGRAMME: INDIVIDUAL-LEVEL DATA ANALYSIS
IMPACT OF DELAYED SCREENING INVITATIONS DUE TO COVID-19 ON OUTCOMES OF THE DUTCH FIT-BASED COLORECTAL CANCER SCREENING PROGRAMME: INDIVIDUAL-LEVEL DATA ANALYSIS

Manon C.W. Spaander  et al.

THE EFFECTIVENESS OF PERSONALIZED COLORECTAL CANCER SCREENING BASED ON PRIOR FECAL HEMOGLOBIN CONCENTRATION: PERFECT-FIT STUDY PROTOCOL
THE EFFECTIVENESS OF PERSONALIZED COLORECTAL CANCER SCREENING BASED ON PRIOR FECAL HEMOGLOBIN CONCENTRATION: PERFECT-FIT STUDY PROTOCOL

Manon C.W. Spaander  et al.

COST-EFFECTIVENESS OF COLORECTAL CANCER SURVEILLANCE IN HODGKIN LYMPHOMA SURVIVORS
COST-EFFECTIVENESS OF COLORECTAL CANCER SURVEILLANCE IN HODGKIN LYMPHOMA SURVIVORS

Manon C.W. Spaander  et al.

SCREENING FOR SYNCHRONOUS SECOND PRIMARY ESOPHAGEAL TUMOR IN PATIENTS WITH HEAD AND NECK CANCER
SCREENING FOR SYNCHRONOUS SECOND PRIMARY ESOPHAGEAL TUMOR IN PATIENTS WITH HEAD AND NECK CANCER

Manon C.W. Spaander  et al.

ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)
ENDOSCOPIC FOLLOW-UP OF RADICALLY RESECTED SUBMUCOSAL ADENOCARCINOMA IN BARRETT’S ESOPHAGUS: PRELIMINARY RESULTS OF AN ONGOING PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT REGISTRY (PREFER TRIAL)

Manon C.W. Spaander  et al.

PREDICTORS OF GASTROINTESTINAL TRANSIT TIMES OF COLON CAPSULE ENDOSCOPY
PREDICTORS OF GASTROINTESTINAL TRANSIT TIMES OF COLON CAPSULE ENDOSCOPY

Manon C.W. Spaander  et al.

SCREENING FOR METACHRONOUS ESOPHAGEAL SECOND PRIMARY TUMORS IN PATIENTS WITH HEAD AND NECK CANCER
SCREENING FOR METACHRONOUS ESOPHAGEAL SECOND PRIMARY TUMORS IN PATIENTS WITH HEAD AND NECK CANCER

Manon C.W. Spaander  et al.

RISK OF INTERVAL COLORECTAL CANCER AFTER NEGATIVE FIT BY QUANTITATIVE FIT-RESULT IN THE DUTCH CRC SCREENING PROGRAM
RISK OF INTERVAL COLORECTAL CANCER AFTER NEGATIVE FIT BY QUANTITATIVE FIT-RESULT IN THE DUTCH CRC SCREENING PROGRAM

Manon C.W. Spaander  et al.

ABERRANT P53 EXPRESSION IS THE STRONGEST PREDICTOR FOR NEOPLASTIC PROGRESSION IN PATIENTS WITH BARRETT’S ESOPHAGUS
ABERRANT P53 EXPRESSION IS THE STRONGEST PREDICTOR FOR NEOPLASTIC PROGRESSION IN PATIENTS WITH BARRETT’S ESOPHAGUS

Manon C.W. Spaander  et al.

PREVALENCE OF NEOPLASIA AT COLONOSCOPY AMONG TESTICULAR CANCER SURVIVORS TREATED WITH PLATINUM-BASED CHEMOTHERAPY
PREVALENCE OF NEOPLASIA AT COLONOSCOPY AMONG TESTICULAR CANCER SURVIVORS TREATED WITH PLATINUM-BASED CHEMOTHERAPY

Manon C.W. Spaander  et al.

DIAGNOSTIC YIELD USING A FIT-BASED RISK MODEL WAS NOT BETTER THAN FIT ONLY: A RANDOMIZED CONTROLLED TRIAL IN THE SECOND ROUND OF THE DUTCH COLORECTAL CANCER SCREENING PROGRAMME
DIAGNOSTIC YIELD USING A FIT-BASED RISK MODEL WAS NOT BETTER THAN FIT ONLY: A RANDOMIZED CONTROLLED TRIAL IN THE SECOND ROUND OF THE DUTCH COLORECTAL CANCER SCREENING PROGRAMME

Manon C.W. Spaander  et al.

Item 1 - 20 / 29
1
2